Fusion Antibodies (FAB) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Oct 2024 12:32 PM
RNS
Result of AGM
08 Oct 2024 07:00 AM
RNS
AGM statement and trading update
02 Oct 2024 07:00 AM
RNS
Block admission six monthly return
12 Sep 2024 09:54 AM
RNS
Notice of AGM
09 Sep 2024 12:35 PM
RNS
Director/PDMR Shareholding
09 Sep 2024 07:00 AM
RNS
Investor presentation
05 Sep 2024 12:15 PM
RNS
Director/PDMR Shareholding
05 Sep 2024 07:00 AM
RNS
Final Results
28 Aug 2024 07:00 AM
RNS
Expansion to OptiMAL collaboration agreement
22 Jul 2024 12:54 PM
RNS
Director/PDMR Shareholding
18 Jul 2024 07:00 AM
RNS
Launch of New Interactive Investor Hub
04 Jul 2024 07:00 AM
RNS
Trading update
23 May 2024 07:00 AM
RNS
New contract with existing client
02 May 2024 07:00 AM
RNS
Investor presentation
30 Apr 2024 07:00 AM
RNS
Year-end trading statement
16 Apr 2024 07:00 AM
RNS
Change of auditor
15 Apr 2024 07:00 AM
RNS
Contract to develop a bespoke OptiPhage library
02 Apr 2024 02:34 PM
RNS
Block admission six monthly return
28 Mar 2024 05:00 PM
RNS
Total Voting Rights
11 Mar 2024 03:04 PM
RNS
Holding(s) in Company
11 Mar 2024 09:10 AM
RNS
Holding(s) in Company
08 Mar 2024 03:09 PM
RNS
Holding(s) in Company
05 Mar 2024 10:40 AM
RNS
Result of General Meeting and Total Voting Rights
29 Feb 2024 05:00 PM
RNS
Total Voting Rights
27 Feb 2024 07:00 AM
RNS
First purchase order under MSA
14 Feb 2024 07:15 AM
RNS
Grant of options and issue of shares to directors
14 Feb 2024 07:15 AM
RNS
Grant of options and issue of shares to directors
14 Feb 2024 07:00 AM
RNS
Placing to raise £1,375,000
06 Feb 2024 07:00 AM
RNS
Follow-on project award and R&D update
01 Feb 2024 07:00 AM
RNS
HMRC R&D tax credit
04 Dec 2023 12:26 PM
RNS
Director/PDMR Shareholding
04 Dec 2023 07:00 AM
RNS
Half-year Report
28 Nov 2023 07:00 AM
RNS
OptiMAL collaboration agreement
09 Nov 2023 07:00 AM
RNS
Half year trading update
27 Oct 2023 11:57 AM
RNS
Result of AGM
04 Oct 2023 02:45 PM
RNS
Block admission six monthly return
29 Sep 2023 07:00 AM
RNS
Final Results
29 Aug 2023 07:00 AM
RNS
Update on AI/ML-Ab service offering
24 Aug 2023 07:00 AM
RNS
Appointment of interim CFO
21 Aug 2023 07:00 AM
RNS
Update on AI/ML-Ab™ antibody discovery service
14 Aug 2023 07:00 AM
RNS
Update on restructure and cost savings
30 Jun 2023 05:00 PM
RNS
Total Voting Rights
16 Jun 2023 10:09 AM
RNS
Holding(s) in Company
15 Jun 2023 09:45 AM
RNS
Holding(s) in Company
13 Jun 2023 02:44 PM
RNS
Holding(s) in Company
12 Jun 2023 03:34 PM
RNS
Holding(s) in Company
12 Jun 2023 11:02 AM
RNS
Director/PDMR Shareholding
08 Jun 2023 10:39 AM
RNS
Result of GM and total voting rights
31 May 2023 05:00 PM
RNS
Total Voting Rights
26 May 2023 04:57 PM
RNS
Holding(s) in Company

Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.

FAB share price launched at 165p in 2017.

UK 100

Latest directors dealings